Actively Recruiting
Study of Faricimab Injections Using a Personalized Treat-and-Extend Plan for Patients with Untreated Polypoidal Choroidal Vasculopathy
Led by Yeungnam University College of Medicine · Updated on 2026-03-10
50
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of a personalized treat-and-extend regimen of faricimab in people with treatment-naive polypoidal choroidal vasculopathy, a condition affecting the eye. This Phase 3 study focuses on how well faricimab works and how long its effects last in improving vision and reducing disease activity. Participants will receive intravitreal injections of faricimab, delivered with a fine needle into the eye after applying anesthetic drops. Following an initial loading phase, all patients enter a treat-and-extend phase starting with injections every 8 weeks. Depending on signs of disease activity like fluid in the retina or vision loss, the interval between injections may be extended by 4 weeks up to 24 weeks, shortened by 4 weeks to a minimum of 4 weeks, or maintained as is. During the study, participants will have regular eye exams including imaging scans to monitor fluid, retinal thickness, and lesion characteristics at multiple time points up to week 96. Researchers will track vision changes and treatment intervals, as well as any treatment-related side effects. The main measurement is the proportion of patients reaching an injection interval of 16 weeks or more by week 96, with ongoing assessments throughout the nearly two-year study period.
CONDITIONS
Brief Title
Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here